Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Up - Here's Why

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report)'s share price gapped up before the market opened on Friday . The stock had previously closed at $29.90, but opened at $32.25. Dianthus Therapeutics shares last traded at $30.56, with a volume of 27,707 shares.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Oppenheimer assumed coverage on Dianthus Therapeutics in a research note on Thursday, October 3rd. They set an "outperform" rating and a $48.00 price target for the company. Baird R W raised Dianthus Therapeutics to a "strong-buy" rating in a report on Friday, July 26th. HC Wainwright reaffirmed a "buy" rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a report on Thursday, September 26th. Wedbush dropped their price objective on Dianthus Therapeutics from $38.00 to $36.00 and set an "outperform" rating on the stock in a report on Friday, August 9th. Finally, Robert W. Baird started coverage on Dianthus Therapeutics in a report on Friday, July 26th. They set an "outperform" rating and a $58.00 price objective on the stock. Eight investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $45.86.

Dianthus Therapeutics Stock Down 2.8 %

The company has a market cap of $853.49 million, a price-to-earnings ratio of -5.21 and a beta of 1.84. The company has a fifty day simple moving average of $27.75 and a two-hundred day simple moving average of $26.45.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.15). The firm had revenue of $2.17 million during the quarter, compared to analyst estimates of $1.07 million. Dianthus Therapeutics had a negative net margin of 1,376.42% and a negative return on equity of 21.03%. On average, research analysts predict that Dianthus Therapeutics, Inc. will post -2.28 EPS for the current year.

Institutional Trading of Dianthus Therapeutics

A number of large investors have recently made changes to their positions in the stock. Quest Partners LLC boosted its stake in shares of Dianthus Therapeutics by 112,400.0% during the third quarter. Quest Partners LLC now owns 1,125 shares of the company's stock valued at $31,000 after acquiring an additional 1,124 shares during the last quarter. SG Americas Securities LLC boosted its stake in shares of Dianthus Therapeutics by 104.0% during the third quarter. SG Americas Securities LLC now owns 8,839 shares of the company's stock valued at $242,000 after acquiring an additional 4,506 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new stake in shares of Dianthus Therapeutics during the second quarter valued at $236,000. Point72 Asia Singapore Pte. Ltd. boosted its stake in shares of Dianthus Therapeutics by 281.9% during the second quarter. Point72 Asia Singapore Pte. Ltd. now owns 39,504 shares of the company's stock valued at $1,022,000 after acquiring an additional 29,159 shares during the last quarter. Finally, Point72 DIFC Ltd purchased a new position in Dianthus Therapeutics during the second quarter worth about $334,000. Institutional investors and hedge funds own 47.53% of the company's stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.